---
title: "SHENGDA BIO-PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 53.34 million yuan, a year-on-year increase of 146.04%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263323515.md"
description: "According to the Zhitong Finance APP, SHENGDA BIO-PHARM disclosed its third-quarter report for 2025. The company achieved revenue of 621 million yuan in the first three quarters, a year-on-year increase of 2.04%; net profit attributable to the parent company was 53.34 million yuan, a year-on-year increase of 146.04%; net profit excluding non-recurring gains and losses was 47.49 million yuan, a year-on-year increase of 393.96%; basic earnings per share were 0.30 yuan"
datetime: "2025-10-29T14:41:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263323515.md)
  - [en](https://longbridge.com/en/news/263323515.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263323515.md)
generator: "portal-rs"
---

# SHENGDA BIO-PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 53.34 million yuan, a year-on-year increase of 146.04%

According to the Zhitong Finance APP, SHENGDA BIO-PHARM (603079.SH) disclosed its third-quarter report for 2025. The company achieved revenue of 621 million yuan in the first three quarters, a year-on-year increase of 2.04%; the net profit attributable to shareholders was 53.34 million yuan, a year-on-year increase of 146.04%; the net profit excluding non-recurring items was 47.49 million yuan, a year-on-year increase of 393.96%; and the basic earnings per share were 0.30 yuan

### Related Stocks

- [603079.CN](https://longbridge.com/en/quote/603079.CN.md)

## Related News & Research

- [Here are some of REI’s best Labor Day sale deals](https://longbridge.com/en/news/297820309.md)
- [Biohit says scientific review backs serum biomarker triage to target endoscopy for gastric cancer risk](https://longbridge.com/en/news/297887371.md)
- [Reallusion AI Studio 1.1 Major Update: Standalone Application, Seedance 2.5, and Upgraded AI Actor Creator](https://longbridge.com/en/news/297783180.md)
- [03:32 ETLundbeck to highlight mechanistic insights on bexicaserin's dual mode of action at the European Epilepsy Congress](https://longbridge.com/en/news/297876004.md)
- [Cleo Diagnostics to Commence Analytical Validation of Pre-Surgical Ovarian Cancer Blood Test](https://longbridge.com/en/news/297848437.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**